TapewireFind a company

person · Reporting owner

Fallon John A.

Disclosed activity across 4 companies

Tapewire entity
73117
SEC CIK
0001560152

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169DirectorNovember 12, 2025November 14, 2025
EXACT SCIENCES CORPEXAS · Entity 56619DirectorJuly 30, 2018August 01, 2018
INSULET CORPPODD · Entity 3516DirectorMay 21, 2021May 25, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COLLEGIUM PHARMACEUTICAL, INC

Report date November 12, 2025 · Filed November 14, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect64,634 Ending reported balance After 2025-11-12 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2025-11-12 · Exercise / conversion · Acquired 15,000 · Balance 79,634

Row 2 · 2025-11-12 · Exercise / conversion · Acquired 19,853 · Balance 99,487

Row 3 · 2025-11-12 · Sale · Disposed 34,853 · Balance 64,634

F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.805 to $47.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $16.49 · Expires 2026-06-09Direct0 Reported balance After 2025-11-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-11-12 · Exercise / conversion · Disposed 15,000 · Balance 0

F2: The option is fully vested and exercisable.

Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $9.33 · Expires 2027-05-24Direct0 Reported balance After 2025-11-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-11-12 · Exercise / conversion · Disposed 19,853 · Balance 0

F2: The option is fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.805 to $47.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The option is fully vested and exercisable.

EXACT SCIENCES CORP

Report date July 30, 2018 · Filed August 01, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect33,767 Reported balance After 2018-07-30 transaction · row 1
1 source row

Row 1 · 2018-07-30 · Sale · Disposed 2,373 · Balance 33,767

F1: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock.

INSULET CORP

Report date May 21, 2021 · Filed May 25, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect14,498 Ending reported balance After 2021-05-21 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2021-05-21 · Exercise / conversion · Acquired 2,235 · Balance 16,733

Row 2 · 2021-05-21 · Exercise / conversion · Acquired 3,587 · Balance 20,320

Row 3 · 2021-05-21 · Sale · Disposed 2,235 · Balance 18,085

Row 4 · 2021-05-21 · Sale · Disposed 3,587 · Balance 14,498

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.87 · Expires 2026-05-11Direct0 Reported balance After 2021-05-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2021-05-21 · Exercise / conversion · Disposed 2,235 · Balance 0

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.60 · Expires 2027-05-17Direct0 Reported balance After 2021-05-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2021-05-21 · Exercise / conversion · Disposed 3,587 · Balance 0

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMAG PHARMACEUTICALS, INC.

Report date November 16, 2020 · Filed November 17, 2020

Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2020-11-16 transaction · row 1
1 source row

Row 1 · 2020-11-16 · Disposition to issuer · Disposed 37,362 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-11-16 · Disposition to issuer · Disposed 6,000 · Balance 0

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-11-16 · Disposition to issuer · Disposed 2,534 · Balance 0

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-11-16 · Disposition to issuer · Disposed 3,575 · Balance 0

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2020-11-16 · Disposition to issuer · Disposed 12,787 · Balance 0

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2020-11-16 · Disposition to issuer · Disposed 10,110 · Balance 0

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2020-11-16 · Disposition to issuer · Disposed 7,543 · Balance 0

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2020-11-16 · Disposition to issuer · Disposed 17,326 · Balance 0

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2020-11-16 · Disposition to issuer · Disposed 21,289 · Balance 0

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 12, 2025 Filed Nov 14, 2025 21:10 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionStock Option (Right to Purchase) · Derivative 19,853 $0.00 Strike: $9.33 $0.00
Disclosure

SEC source: 0001560152-25-000004 · form4-11142025_091156.xml · derivative · entry 5

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,853 shares

Expires 2027-05-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 21:10 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionStock Option (Right to Purchase) · Derivative 15,000 $0.00 Strike: $16.49 $0.00
Disclosure

SEC source: 0001560152-25-000004 · form4-11142025_091156.xml · derivative · entry 4

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2026-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 21:10 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 SaleCommon Stock 34,853 $47.21 $1,645,535.60
Disclosure

SEC source: 0001560152-25-000004 · form4-11142025_091156.xml · nonDerivative · entry 3

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,634

F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.805 to $47.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 21:10 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionCommon Stock 19,853 $9.33 $185,228.49
Disclosure

SEC source: 0001560152-25-000004 · form4-11142025_091156.xml · nonDerivative · entry 2

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,487

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 21:10 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 Exercise / conversionCommon Stock 15,000 $16.49 $247,350.00
Disclosure

SEC source: 0001560152-25-000004 · form4-11142025_091156.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,634

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 21:43 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 9,791 $0.00 $0.00
Disclosure

SEC source: 0001062993-25-009810 · form4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,634

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Read SEC document
May 16, 2024 Filed May 16, 2024 23:22 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 7,693 $0.00 $0.00
Disclosure

SEC source: 0001062993-24-010539 · form4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,843

F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Read SEC document
May 18, 2023 Filed May 19, 2023 20:39 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 9,792 $0.00 $0.00
Disclosure

SEC source: 0001062993-23-011816 · form4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,150

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 18, 2024, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.

Read SEC document
May 19, 2022 Filed May 23, 2022 20:43 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 14,035 $0.00 $0.00
Disclosure

SEC source: 0001062993-22-013301 · form4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,358

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 19, 2023, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.

Read SEC document
May 21, 2021 Filed May 25, 2021 20:51 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionStock Option (Right to Buy) · Derivative 3,587 $0.00 Strike: $40.60 $0.00
Disclosure

SEC source: 0001127602-21-018010 · form4.xml · derivative · entry 6

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,587 shares

Expires 2027-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 21, 2021 Filed May 25, 2021 20:51 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionStock Option (Right to Buy) · Derivative 2,235 $0.00 Strike: $28.87 $0.00
Disclosure

SEC source: 0001127602-21-018010 · form4.xml · derivative · entry 5

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,235 shares

Expires 2026-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 21, 2021 Filed May 25, 2021 20:51 UTC INSULET CORP PODD · Entity 3516 SaleCommon Stock 3,587 $253.21 $908,246.34
Disclosure

SEC source: 0001127602-21-018010 · form4.xml · nonDerivative · entry 4

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,498

Read SEC document
May 21, 2021 Filed May 25, 2021 20:51 UTC INSULET CORP PODD · Entity 3516 SaleCommon Stock 2,235 $253.61 $566,808.29
Disclosure

SEC source: 0001127602-21-018010 · form4.xml · nonDerivative · entry 3

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,085

Read SEC document
May 21, 2021 Filed May 25, 2021 20:51 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionCommon Stock 3,587 $40.60 $145,632.20
Disclosure

SEC source: 0001127602-21-018010 · form4.xml · nonDerivative · entry 2

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,320

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 21, 2021 Filed May 25, 2021 20:51 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionCommon Stock 2,235 $28.87 $64,524.45
Disclosure

SEC source: 0001127602-21-018010 · form4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,733

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 20, 2021 Filed May 24, 2021 21:20 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 9,941 $0.00 $0.00
Disclosure

SEC source: 0001192482-21-000457 · edgar.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,323

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2022, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:41 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 21,289 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126318 · a4.xml · derivative · entry 9

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,289 shares

Expires not disclosed

F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:41 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 17,326 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126318 · a4.xml · derivative · entry 8

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,326 shares

Expires not disclosed

F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:41 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 7,543 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126318 · a4.xml · derivative · entry 7

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,543 shares

Expires not disclosed

F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:41 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 10,110 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126318 · a4.xml · derivative · entry 6

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,110 shares

Expires not disclosed

F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:41 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 12,787 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126318 · a4.xml · derivative · entry 5

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,787 shares

Expires not disclosed

F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:41 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 3,575 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126318 · a4.xml · derivative · entry 4

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,575 shares

Expires not disclosed

F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:41 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 2,534 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126318 · a4.xml · derivative · entry 3

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,534 shares

Expires not disclosed

F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:41 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 6,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126318 · a4.xml · derivative · entry 2

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:41 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerCommon Stock 37,362 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126318 · a4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:05 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionStock Option (Right to Buy) · Derivative 3,000 $0.00 Strike: $28.87 $0.00
Disclosure

SEC source: 0001127602-20-028354 · form4.xml · derivative · entry 3

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,235

Underlying: Common Stock · 3,000 shares

Expires 2026-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:05 UTC INSULET CORP PODD · Entity 3516 SaleCommon Stock 3,000 $230.00 $690,000.00
Disclosure

SEC source: 0001127602-20-028354 · form4.xml · nonDerivative · entry 2

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,498

F1 · price: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.

Read SEC document
November 04, 2020 Filed Nov 6, 2020 21:05 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionCommon Stock 3,000 $28.87 $86,610.00
Disclosure

SEC source: 0001127602-20-028354 · form4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,498

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.

Read SEC document
November 02, 2020 Filed Nov 3, 2020 21:05 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionStock Option (Right to Buy) · Derivative 4,000 $0.00 Strike: $35.11 $0.00
Disclosure

SEC source: 0001127602-20-027995 · form4.xml · derivative · entry 3

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires 2024-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on April 30, 2015, 25% of the total award vesting on April 30, 2016 and 25% of the total award vesting on April 30, 2017, subject to continued service as a director or consultant.

Read SEC document
November 02, 2020 Filed Nov 3, 2020 21:05 UTC INSULET CORP PODD · Entity 3516 SaleCommon Stock 4,000 $225.00 $900,000.00
Disclosure

SEC source: 0001127602-20-027995 · form4.xml · nonDerivative · entry 2

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,498

F1 · price: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.

Read SEC document
November 02, 2020 Filed Nov 3, 2020 21:05 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionCommon Stock 4,000 $35.11 $140,440.00
Disclosure

SEC source: 0001127602-20-027995 · form4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,498

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 16:49 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 GrantStock Option (Right to Buy) · Derivative 21,289 Not disclosed Strike: $8.52 Not disclosed
Disclosure

SEC source: 0000792977-20-000060 · wf-form4_159130377601364.xml · derivative · entry 2

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,289

Underlying: Common Stock · 21,289 shares

Expires 2030-06-02

F2 · price: Not applicable.

F3 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 16:49 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 GrantCommon Stock 10,269 Not disclosed Not disclosed
Disclosure

SEC source: 0000792977-20-000060 · wf-form4_159130377601364.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,362

F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer.

F2 · price: Not applicable.

Read SEC document
May 28, 2020 Filed Jun 1, 2020 20:57 UTC INSULET CORP PODD · Entity 3516 GrantCommon Stock 1,029 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-018247 · form4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,498

F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2021 and are settled in shares of common stock on a one-for-one basis.

Read SEC document
May 20, 2020 Filed May 22, 2020 20:23 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantStock Option (Right to Purchase) · Derivative 8,095 $0.00 Strike: $22.05 $0.00
Disclosure

SEC source: 0001192482-20-000364 · edgar.xml · derivative · entry 2

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,095

Underlying: Common Stock · 8,095 shares

Expires 2030-05-20

F2 · derivative.exercise_date: The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer.

Read SEC document
May 20, 2020 Filed May 22, 2020 20:23 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 4,047 $0.00 $0.00
Disclosure

SEC source: 0001192482-20-000364 · edgar.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,382

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.

Read SEC document
November 18, 2019 Filed Nov 19, 2019 21:08 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionStock Option (Right to Buy) · Derivative 4,000 $0.00 Strike: $30.04 $0.00
Disclosure

SEC source: 0001127602-19-033198 · form4.xml · derivative · entry 8

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires 2023-06-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option is subject to the following vesting schedule: 50% of the total award shall vest on April 30, 2014, 25% of the total award shall vest on April 30, 2015 and 25% of the total award shall vest on April 30, 2016, subject to continued service as a director or consultant.

Read SEC document
November 18, 2019 Filed Nov 19, 2019 21:08 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionStock Option (Right to Buy) · Derivative 5,525 $0.00 Strike: $27.37 $0.00
Disclosure

SEC source: 0001127602-19-033198 · form4.xml · derivative · entry 7

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,525 shares

Expires 2025-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on April 30, 2016, 25% of the total award vesting on April 30, 2017 and 25% of the total award vesting on April 30, 2018, subject to continued service as a director or consultant.

Read SEC document
November 18, 2019 Filed Nov 19, 2019 21:08 UTC INSULET CORP PODD · Entity 3516 SaleCommon Stock 9,525 $181.41 $1,727,917.87
Disclosure

SEC source: 0001127602-19-033198 · form4.xml · nonDerivative · entry 5

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,469

F1 · price: The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $181.18 to $182.82. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
November 18, 2019 Filed Nov 19, 2019 21:08 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionCommon Stock 4,000 $30.04 $120,160.00
Disclosure

SEC source: 0001127602-19-033198 · form4.xml · nonDerivative · entry 4

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 18, 2019 Filed Nov 19, 2019 21:08 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionCommon Stock 5,525 $27.37 $151,219.25
Disclosure

SEC source: 0001127602-19-033198 · form4.xml · nonDerivative · entry 3

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 15, 2019 Filed Nov 19, 2019 21:08 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionStock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $21.35 $0.00
Disclosure

SEC source: 0001127602-19-033198 · form4.xml · derivative · entry 6

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2022-11-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% of the total award vesting on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant.

Read SEC document
November 15, 2019 Filed Nov 19, 2019 21:08 UTC INSULET CORP PODD · Entity 3516 SaleCommon Stock 5,000 $180.07 $900,325.00
Disclosure

SEC source: 0001127602-19-033198 · form4.xml · nonDerivative · entry 2

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,469

Read SEC document
November 15, 2019 Filed Nov 19, 2019 21:08 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionCommon Stock 5,000 $21.35 $106,750.00
Disclosure

SEC source: 0001127602-19-033198 · form4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,469

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 30, 2019 Filed Jun 3, 2019 21:37 UTC INSULET CORP PODD · Entity 3516 GrantCommon Stock 1,726 $0.00 $0.00
Disclosure

SEC source: 0001127602-19-020531 · form4.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,469

F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2020 and are settled in shares of common stock on a one-for-one basis.

Read SEC document
May 16, 2019 Filed May 20, 2019 07:27 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 GrantStock Option (Right to Buy) · Derivative 17,326 Not disclosed Strike: $10.78 Not disclosed
Disclosure

SEC source: 0000792977-19-000104 · wf-form4_155835163385617.xml · derivative · entry 2

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,326

Underlying: Common Stock · 17,326 shares

Expires 2029-05-16

F2 · price: Not applicable.

F3 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders.

Read SEC document
May 16, 2019 Filed May 20, 2019 07:27 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 GrantCommon Stock 8,116 Not disclosed Not disclosed
Disclosure

SEC source: 0000792977-19-000104 · wf-form4_155835163385617.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,093

F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer.

F2 · price: Not applicable.

Read SEC document
April 25, 2019 Filed Apr 29, 2019 22:55 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantStock Option (Right to Purchase) · Derivative 9,414 $0.00 Strike: $14.57 $0.00
Disclosure

SEC source: 0001192482-19-000222 · edgar.xml · derivative · entry 2

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,414

Underlying: Common Stock · 9,414 shares

Expires 2029-04-25

F2 · derivative.exercise_date: The option vests and becomes exercisable on April 25, 2020, subject to the director's continued service with the issuer.

Read SEC document
April 25, 2019 Filed Apr 29, 2019 22:55 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 4,707 $0.00 $0.00
Disclosure

SEC source: 0001192482-19-000222 · edgar.xml · nonDerivative · entry 1

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,335

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 25, 2020, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.

Read SEC document
March 20, 2019 Filed Mar 22, 2019 20:16 UTC INSULET CORP PODD · Entity 3516 Exercise / conversionStock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $21.35 $0.00
Disclosure

SEC source: 0001127602-19-012921 · form4.xml · derivative · entry 3

Fallon John A. · CIK 0001560152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2022-11-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% of the total award vesting on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.